Cardiff Oncology shares plunge after Q2 earnings miss
Johanna Roberts, Executive Vice President, General Counsel & Secretary at Penumbra Inc (NYSE:PEN), recently executed a series of stock sales totaling $154,903, according to a Form 4 filing with the Securities and Exchange Commission. The transactions, carried out on June 2, 2025, involved the sale of common stock at prices ranging from $256.06 to $266.94 per share.
Roberts sold a total of 597 shares, with the sales conducted under a Rule 10b5-1 trading plan. Following these transactions, Roberts retains ownership of 64,714 shares of Penumbra stock. A portion of these shares is subject to vesting conditions. The company has demonstrated solid performance with 13.17% revenue growth in the last twelve months, though analysts note it’s trading at relatively high earnings multiples.
This series of transactions reflects Roberts’ ongoing engagement with the company’s stock, as she continues to manage her holdings in Penumbra. For deeper insights into PEN’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Penumbra has reported notable earnings and revenue growth, capturing investors’ attention. The company achieved a year-over-year sales increase of 16.3%, reaching $324.1 million, and earnings per share surged by 102.8% to $0.83, surpassing Wall Street estimates. UBS analyst Priya Sachdeva raised the price target for Penumbra shares to $330, maintaining a Buy rating, while Stifel and BTIG also increased their targets to $318 and $320, respectively. These adjustments follow Penumbra’s strong performance in its U.S. Thrombectomy business, which saw a 25% sales increase. Penumbra’s management has reaffirmed its revenue guidance for the year, projecting a 12-14% increase, translating to a target range of $1.34 billion to $1.36 billion. The company has also submitted a 510K for its Thunderbolt product, with potential commercialization in the second half of 2025. Piper Sandler analyst Matt O’Brien indicated that Penumbra’s Thunderbolt device might receive regulatory approval sooner than expected, which could further boost the company’s revenue. Investors are closely monitoring these developments, as early approval could enhance Penumbra’s competitive position in the medical device sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.